Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Crystallin gene expression during rat lens development.

Authors: Aarts, HJ  Lubsen, NH  Schoenmakers, JG 
Citation: Aarts HJ, etal., Eur J Biochem 1989 Jul 15;183(1):31-6.
Pubmed: (View Article at PubMed) PMID:2753045

The analysis of the developmental pattern of the alpha A-, alpha B-, beta B1-, beta B2-, beta B3-, beta A3/A1-, and beta s-crystallin genes during fetal and postnatal development of the rat shows that the differential regulation of crystallin synthesis relies on differential gene shutdown rather than differential gene activation; that is, all crystallin genes are active during early development but turn off at different stages. The only two exceptions to this rule are the alpha B- and beta s-crystallin genes. The alpha B-crystallin gene transcript becomes first detectable at 18 days of fetal development, while the beta s-crystallin gene appears to be active only in the postnatal period. We also determined the absolute numbers of the alpha A-, alpha B-, beta B1-, beta B2-, beta B3-, beta A3/A1-, beta s-, and gamma-crystallin gene transcripts present in the lens at various times after birth. Comparison of these RNA data with the published protein data shows that the alpha B- and beta B2-crystallin RNAs are relatively overrepresented, suggesting the possibility that these two RNA species are not used as efficiently as other crystallin mRNAs. Examination of the known (hamster) alpha B-crystallin sequence and elucidation of the (rat) beta B2-crystallin sequence yielded no evidence for aberrant codon usage. These two RNAs have one sequence motif in common: they are the only crystallin mRNAs in which the translation initiation codon is preceded by CCACC.

Annotation

Gene Ontology Annotations
Objects Annotated
Objects referenced in this article

Additional Information

 
CRRD Object Information
CRRD ID: 1298814
Created: 2004-06-01
Species: All species
Last Modified: 2004-06-01
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.